MEDICATION | DOSAGE | ON- OR OFF-LABEL? | NUMBER OF SUBJECTS (% OF TOTAL) | PARTIAL USE (NUMBER OF SUBJECTS) |
---|---|---|---|---|
LIRAGLUTIDE | 1.8 mg daily | Off-label (during the study period) On-label (2016 Nov) | 39 (90.7%) | 1 < 6 months 1 6–11 months |
SGLT2 INHIBITORS | Canagliflozin 300 mg daily Dapagliflozin 10 mg daily | Off-label | 37 (86.0%) | 5 < 6 months |
ORLISTAT | 120 mg B.I.D. | On-label | 34 (79.1%) | 4 < 6 months 3 6–11 months |
METFORMIN | 2000 mg daily | Off-label | 28 (65.1%) | 2 < 6 months |
BUPROPION + NALTREXONE | 300 mg + 32 mg daily | On-label (USA) Off-label (Brazil) | 25 (58.1%) | 2 < 6 months 10 6–11 months |
SIBUTRAMINE | 10-15 mg daily | On-label (Brazil) Prohibited (USA) | 23 (53.5%) | 3 < 6 months |
TOPIRAMATE | 100 mg daily | On-label (USA) (when combined with phentermine) Off-label (Brazil) | 13 (30.2%) | 4 < 6 months |
TESTOSTERONE | 1000Â mg I.M. every 3Â months | On-label (when hypogonadism is present) | 12 (27.9%) | - |
FLUOXETINE | 20-60 mg daily | Off-label | 11 (25.6%) | 1 < 6 months |
SERTRALINE | 50-200 mg daily | Off-label | 10 (23.3%) | 1 < 6 months |